Adagio Medical Secures $19M for Cryoablation Tech

Adagio Medical Holdings ( (ADGM) ) has provided an announcement.

On October 20, 2025, Adagio Medical Holdings announced the closing of a $19 million private placement, aimed at advancing its proprietary Ultra-Low Temperature Cryoablation technologies for ventricular tachycardia. The funds will support FDA submission activities, enhance clinical experience, and expand manufacturing capabilities, positioning Adagio to improve treatment outcomes for VT patients and strengthen its market presence.

The most recent analyst rating on (ADGM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Spark’s Take on ADGM Stock

According to Spark, TipRanks’ AI Analyst, ADGM is a Neutral.

Adagio Medical Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by consistent losses and negative cash flows. Technical analysis indicates a bearish trend, and valuation metrics are unfavorable due to a negative P/E ratio and lack of dividend yield. These factors collectively contribute to a low stock score.

To see Spark’s full report on ADGM stock, click here.

More about Adagio Medical Holdings

Adagio Medical Holdings, Inc. is a medical device company specializing in the development and commercialization of products for treating cardiac arrhythmias using its innovative, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. The company focuses on the treatment of ventricular tachycardia (VT) with its vCLAS™ Cryoablation System, which is CE Marked and under evaluation in the U.S. FULCRUM-VT IDE Pivotal Study.

Average Trading Volume: 334,590

Technical Sentiment Signal: Sell

Current Market Cap: $21.15M

For a thorough assessment of ADGM stock, go to TipRanks’ Stock Analysis page.